Targovax: Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications. Strong results from Part 1 (ONCOS-102/Keytruda combo) trial in anti-PD1 refractory melanoma: 33% ORR in 9 pts: 1 CR, 2 PRs; immune activation demonstrated in all 9 pts. Jan 2020: exp randomized data, Ph 1b/ 2 (mesothelioma, n=31) w/chemo
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Oncology
Finance
Pre-earnings
Industry
Biotechnology
Listing
Europe, Public
Market Cap
<100MM
Therapeutic Modalities
Platform Technology
Website:
Address:
Lilleakerveien 2 C
Oslo, NO-0283
Norway

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout KOL Day

New York City, November 15, 2019

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.